miR-143 inhibits bladder cancer cell proliferation and enhances their sensitivity to gemcitabine by repressing IGF-1R signaling

Wang,Hengbing; Li,Qi; Niu,Xiaobing; Wang,Gongcheng; Zheng,Sinian; Fu,Guangbo; Wang,Zengjun

doi:10.3892/ol.2016.5388

miR-143 inhibits bladder cancer cell proliferation and enhances their sensitivity to gemcitabine by repressing IGF-1R signaling

Authors:
- Hengbing Wang
- Qi Li
- Xiaobing Niu
- Gongcheng Wang
- Sinian Zheng
- Guangbo Fu
- Zengjun Wang
View Affiliations

Affiliations: Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China, Department of Pathology, The Affiliated Drum Tower Hospital, Nanjing University Medical School, Nanjing, Jiangsu 210008, P.R. China, Department of Urology, Huai'an First People's Hospital, Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China
Published online on: November 16, 2016 https://doi.org/10.3892/ol.2016.5388
Pages: 435-440

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

microRNAs (miRNAs) are a class of small RNAs that regulate gene expression. It has been demonstrated that aberrant miRNA expression is associated with cancer development and carcinogenesis. Altered miRNA expression has been suggested to occur in bladder cancer. In other cancer systems, studies have indicated that miR‑143, as a tumor suppressor gene, plays essential roles in cancer progression. However, its role in bladder cancer has yet to be elucidated. In the present study, we observed that miR‑143 expression was downregulated in human bladder cancer tissues and cells, and that its levels were negatively correlated with bladder cancer clinical stages. We further demonstrated that insulin-like growth factor‑1 receptor (IGF‑1R) is a functional target of miR‑143. Their expression levels were inversely correlated in bladder cancer samples. Overexpression of miR‑143 inhibited cell proliferation and promoted chemosensitivity of bladder cancer 5637 cells to gemcitabine. Consistently, small interfering RNA‑mediated knockdown of IGF‑1R phenocopied miR‑143 overexpression. Notably, the expression of IGF‑1R is a predictor of patient prognosis. Collectively, our findings indicate that miR‑143 is a valuable biomarker for bladder cancer. The miR‑143/IGF‑1R axis is associated with bladder cancer drug resistance and patient survival.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
2	Dinney CP, McConkey DJ, Millikan RE, Wu X, Bar-Eli M, Adam L, Kamat AM, Siefker-Radtke AO, Tuziak T, Sabichi AL, et al: Focus on bladder cancer. Cancer Cell. 6:111–116. 2004. View Article : Google Scholar : PubMed/NCBI
3	Jebar AH, Hurst CD, Tomlinson DC, Johnston C, Taylor CF and Knowles MA: FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene. 24:5218–5225. 2005. View Article : Google Scholar : PubMed/NCBI
4	McConkey DJ, Lee S, Choi W, Tran M, Majewski T, Lee S, Siefker-Radtke A, Dinney C and Czerniak B: Molecular genetics of bladder cancer: emerging mechanisms of tumor initiation and progression. Urol Oncol. 28:429–440. 2010. View Article : Google Scholar : PubMed/NCBI
5	Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A and Palou-Redorta J: European Association of Urology (EAU): EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 54:303–314. 2008. View Article : Google Scholar : PubMed/NCBI
6	Lamm DL, Riggs DR, Traynelis CL and Nseyo UO: Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol. 153:1444–1450. 1995. View Article : Google Scholar : PubMed/NCBI
7	Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
8	Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
9	Esquela-Kerscher A and Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006. View Article : Google Scholar : PubMed/NCBI
10	Dyrskjøt L, Ostenfeld MS, Bramsen JB, Silahtaroglu AN, Lamy P, Ramanathan R, Fristrup N, Jensen JL, Andersen CL, Zieger K, et al: Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res. 69:4851–4860. 2009. View Article : Google Scholar : PubMed/NCBI
11	Rubin R and Baserga R: Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity. Lab Invest. 73:311–331. 1995.PubMed/NCBI
12	Macaulay VM: Insulin-like growth factors and cancer. Br J Cancer. 65:311–320. 1992. View Article : Google Scholar : PubMed/NCBI
13	Hanahan D and Weinberg RA: The hallmarks of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
14	Baserga R: Controlling IGF-receptor function: a possible strategy for tumor therapy. Trends Biotechnol. 14:150–152. 1996. View Article : Google Scholar : PubMed/NCBI
15	Qian X, Yu J, Yin Y, He J, Wang L, Li Q, Zhang LQ, Li CY, Shi ZM, Xu Q, et al: MicroRNA-143 inhibits tumor growth and angiogenesis and sensitizes chemosensitivity to oxaliplatin in colorectal cancers. Cell Cycle. 12:1385–1394. 2013. View Article : Google Scholar : PubMed/NCBI
16	Rochester MA, Patel N, Turney BW, Davies DR, Roberts IS, Crew J, Protheroe A and Macaulay VM: The type 1 insulin-like growth factor receptor is over-expressed in bladder cancer. BJU Int. 100:1396–1401. 2007. View Article : Google Scholar : PubMed/NCBI
17	Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR, et al: Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 33:e1792005. View Article : Google Scholar : PubMed/NCBI
18	Wang X: A PCR-based platform for microRNA expression profiling studies. RNA. 15:716–723. 2009. View Article : Google Scholar : PubMed/NCBI
19	Jing Y, Liu LZ, Jiang Y, Zhu Y, Guo NL, Barnett J, Rojanasakul Y, Agani F and Jiang BH: Cadmium increases HIF-1 and VEGF expression through ROS, ERK, and AKT signaling pathways and induces malignant transformation of human bronchial epithelial cells. Toxicol Sci. 125:10–19. 2012. View Article : Google Scholar : PubMed/NCBI
20	He J, Qian X, Carpenter R, Xu Q, Wang L, Qi Y, Wang ZX, Liu LZ and Jiang BH: Repression of miR-143 mediates Cr (VI)-induced tumor angiogenesis via IGF-IR/IRS1/ERK/IL-8 pathway. Toxicol Sci. 134:26–38. 2013. View Article : Google Scholar : PubMed/NCBI
21	Fang R, Xiao T, Fang Z, Sun Y, Li F, Gao Y, Feng Y, Li L, Wang Y, Liu X, et al: MicroRNA-143 (miR-143) regulates cancer glycolysis via targeting hexokinase 2 gene. J Biol Chem. 287:23227–23235. 2012. View Article : Google Scholar : PubMed/NCBI
22	Gregersen LH, Jacobsen A, Frankel LB, Wen J, Krogh A and Lund AH: MicroRNA-143 down-regulates Hexokinase 2 in colon cancer cells. BMC Cancer. 12:2322012. View Article : Google Scholar : PubMed/NCBI
23	Kent OA, Fox-Talbot K and Halushka MK: RREB1 repressed miR-143/145 modulates KRAS signaling through downregulation of multiple targets. Oncogene. 32:2576–2585. 2013. View Article : Google Scholar : PubMed/NCBI
24	Metalli D, Lovat F, Tripodi F, Genua M, Xu SQ, Spinelli M, Alberghina L, Vanoni M, Baffa R, Gomella LG, et al: The insulin-like growth factor receptor I promotes motility and invasion of bladder cancer cells through Akt- and mitogen-activated protein kinase-dependent activation of paxillin. Am J Pathol. 176:2997–3006. 2010. View Article : Google Scholar : PubMed/NCBI
25	Sekar D, Islam VI Hairul, Thirugnanasambantham K and Saravanan S: Relevance of miR-21 in HIV and non-HIV-related lymphomas. Tumour Biol. 35:8387–8393. 2014. View Article : Google Scholar : PubMed/NCBI
26	Iida K, Fukushi J, Matsumoto Y, Oda Y, Takahashi Y, Fujiwara T, Fujiwara-Okada Y, Hatano M, Nabashima A, Kamura S and Iwamoto Y: miR-125b develops chemoresistance in Ewing sarcoma/primitive neuroectodermal tumor. Cancer Cell Int. 13:212013. View Article : Google Scholar : PubMed/NCBI
27	Han Y, Chen J, Zhao X, Liang C, Wang Y, Sun L, Jiang Z, Zhang Z, Yang R, Chen J, et al: MicroRNA expression signatures of bladder cancer revealed by deep sequencing. PLoS One. 6:e182862011. View Article : Google Scholar : PubMed/NCBI
28	Noguchi S, Mori T, Hoshino Y, Maruo K, Yamada N, Kitade Y, Naoe T and Akao Y: MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells. Cancer Lett. 307:211–220. 2011. View Article : Google Scholar : PubMed/NCBI
29	Ak S, Tunca B, Tezcan G, Cecener G, Egeli U, Yilmazlar T, Ozturk E and Yerci O: MicroRNA expression patterns of tumors in early-onset colorectal cancer patients. J Surg Res. 191:113–122. 2014. View Article : Google Scholar : PubMed/NCBI
30	Ng EK, Li R, Shin VY, Siu JM, Ma ES and Kwong A: MicroRNA-143 is downregulated in breast cancer and regulates DNA methyltransferases 3A in breast cancer cells. Tumour Biol. 35:2591–2598. 2014. View Article : Google Scholar : PubMed/NCBI
31	Hart LS, Dolloff NG, Dicker DT, Koumenis C, Christensen JG, Grimberg A and El-Deiry WS: Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumab. Cell Cycle. 10:2331–2338. 2011. View Article : Google Scholar : PubMed/NCBI
32	Zhao D, Bakirtzi K, Zhan Y, Zeng H, Koon HW and Pothoulakis C: Insulin-like growth factor-1 receptor transactivation modulates the inflammatory and proliferative responses of neurotensin in human colonic epithelial cells. J Biol Chem. 286:6092–6099. 2011. View Article : Google Scholar : PubMed/NCBI
33	Zhu Z, Xu T, Wang L, Wang X, Zhong S, Xu C and Shen Z: MicroRNA-145 directly targets the insulin-like growth factor receptor I in human bladder cancer cells. FEBS Lett. 588:3180–3185. 2014. View Article : Google Scholar : PubMed/NCBI
34	Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, et al: A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 12:395–402. 2007. View Article : Google Scholar : PubMed/NCBI
35	Park BH and Davidson NE: PI3 kinase activation and response to trastuzumab therapy: what's neu with herceptin resistance? Cancer Cell. 12:297–299. 2007. View Article : Google Scholar : PubMed/NCBI
36	Vivanco I and Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2:489–501. 2002. View Article : Google Scholar : PubMed/NCBI
37	Hennessy BT, Smith DL, Ram PT, Lu Y and Mills GB: Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 4:988–1004. 2005. View Article : Google Scholar : PubMed/NCBI